Unravelling the human disposition of [ 14 C]‐vebreltinib: Faecal recovery of parent drug and a major circulating metabolite defines its mass balance profile

Documenti analoghi

• Establishing reference ranges for circulating biomarkers of drug‐induced liver injury in healthy human volunteers 1
  di: Andrea L. Jorgensen, et al.
  Pubblicazione: (2024)
• Circadian time‐dependent effects of experimental colitis on theophylline disposition and toxicity
  di: Yi Yang, et al.
  Pubblicazione: (2024)
• Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients
  di: Miriam S. R. Happ, et al.
  Pubblicazione: (2025)
• Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response
  di: Magnus Ingelman‐Sundberg, et al.
  Pubblicazione: (2024)
• Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
  di: Zhili Jin, et al.
  Pubblicazione: (2026)